Heather Perry Gardner
University of Pennsylvania
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Heather Perry Gardner.
Oncogene | 1998
David E. Jensen; Monja L. Proctor; Sandra T. Marquis; Heather Perry Gardner; Seung I. Ha; Lewis A. Chodosh; Alexander M. Ishov; Niels Tommerup; Henrik Vissing; Yoshitaka Sekido; John D. Minna; Anna Borodovsky; David C. Schultz; Keith D. Wilkinson; Gerd G. Maul; Nickolai A. Barlev; Shelley L. Berger; George C. Prendergast; Frank J. Rauscher
We have identified a novel protein, BAP1, which binds to the RING finger domain of the Breast/Ovarian Cancer Susceptibility Gene product, BRCA1. BAP1 is a nuclear-localized, ubiquitin carboxy-terminal hydrolase, suggesting that deubiquitinating enzymes may play a role in BRCA1 function. BAP1 binds to the wild-type BRCA1-RING finger, but not to germline mutants of the BRCA1-RING finger found in breast cancer kindreds. BAP1 and BRCA1 are temporally and spatially co-expressed during murine breast development and remodeling, and show overlapping patterns of subnuclear distribution. BAP1 resides on human chromosome 3p21.3; intragenic homozgyous rearrangements and deletions of BAP1 have been found in lung carcinoma cell lines. BAP1 enhances BRCA1-mediated inhibition of breast cancer cell growth and is the first nuclear-localized ubiquitin carboxy-terminal hydrolase to be identified. BAP1 may be a new tumor suppressor gene which functions in the BRCA1 growth control pathway.
Proceedings of the National Academy of Sciences of the United States of America | 2009
Gerald Wertheim; Thomas W. Yang; Tien-chi Pan; Anna Ramne; Zhandong Liu; Heather Perry Gardner; Petra Kristel; Bas Kreike; Marc J. van de Vijver; Robert D. Cardiff; Carol Reynolds; Lewis A. Chodosh
We previously identified a SNF1/AMPK-related protein kinase, Hunk, from a mammary tumor arising in an MMTV-neu transgenic mouse. The function of this kinase is unknown. Using targeted deletion in mice, we now demonstrate that Hunk is required for the metastasis of c-myc-induced mammary tumors, but is dispensable for normal development. Reconstitution experiments revealed that Hunk is sufficient to restore the metastatic potential of Hunk-deficient tumor cells, as well as defects in migration and invasion, and does so in a manner that requires its kinase activity. Consistent with a role for this kinase in the progression of human cancers, the human homologue of Hunk is overexpressed in aggressive subsets of carcinomas of the ovary, colon, and breast. In addition, a murine gene expression signature that distinguishes Hunk-wild type from Hunk-deficient mammary tumors predicts clinical outcome in women with breast cancer in a manner consistent with the pro-metastatic function of Hunk in mice. These findings identify a direct role for Hunk kinase activity in metastasis and establish an in vivo function for this kinase.
Journal of Clinical Investigation | 2011
Elizabeth S. Yeh; Thomas W. Yang; Jason J. Jung; Heather Perry Gardner; Robert D. Cardiff; Lewis A. Chodosh
Understanding the molecular pathways that contribute to the aggressive behavior of human cancers is a critical research priority. The SNF1/AMPK-related protein kinase Hunk is overexpressed in aggressive subsets of human breast, ovarian, and colon cancers. Analysis of Hunk(–/–) mice revealed that this kinase is required for metastasis of c-myc–induced mammary tumors but not c-myc–induced primary tumor formation. Similar to c-myc, amplification of the proto-oncogene HER2/neu occurs in 10%–30% of breast cancers and is associated with aggressive tumor behavior. By crossing Hunk(–/–) mice with transgenic mouse models for HER2/neu-induced mammary tumorigenesis, we report that Hunk is required for primary tumor formation induced by HER2/neu. Knockdown and reconstitution experiments in mouse and human breast cancer cell lines demonstrated that Hunk is required for maintenance of the tumorigenic phenotype in HER2/neu-transformed cells. This requirement is kinase dependent and resulted from the ability of Hunk to suppress apoptosis in association with downregulation of the tumor suppressor p27(kip1). Additionally, we find that Hunk is rapidly upregulated following HER2/neu activation in vivo and in vitro. These findings provide what we believe is the first evidence for a role for Hunk in primary tumorigenesis and cell survival and identify this kinase as an essential effector of the HER2/neu oncogenic pathway.
Developmental Biology | 1997
Sandra T. Marquis; Heather Perry Gardner; Lewis A. Chodosh
Developmental Biology | 2000
Lewis A. Chodosh; Heather Perry Gardner; Douglas B. Stairs; Sandra T. Marquis; Philip Leder
Cancer Research | 1999
Lewis A. Chodosh; Celina M. D'Cruz; Heather Perry Gardner; Seung I. Ha; Sandra T. Marquis; Douglas B. Stairs; James Y. Wang; Man Wang
Genomics | 2000
Heather Perry Gardner; Gerald Wertheim; Seung I. Ha; Neal G. Copeland; Debra J. Gilbert; Nancy A. Jenkins; Sandra T. Marquis; Lewis A. Chodosh
Development | 2000
Heather Perry Gardner; George K. Belka; Gerald Wertheim; Jennifer L. Hartman; Seung I. Ha; Phyllis A. Gimotty; Sandra T. Marquis; Lewis A. Chodosh
Genomics | 2000
Heather Perry Gardner; Seung I. Ha; Neal G. Copeland; Debra J. Gilbert; Nancy A. Jenkins; Sandra T. Marquis; Lewis A. Chodosh
Human Molecular Genetics | 1998
Douglas B. Stairs; Heather Perry Gardner; Seung I. Ha; Neal G. Copeland; Debra J. Gilbert; Nancy A. Jenkins; Lewis A. Chodosh